MantaBio
MantaBio is a seed-stage life science tools startup developing an automated microbial detection platform for biopharmaceutical manufacturers to identify contamination during drug production. The Beverly, Massachusetts-based company is in active platform development and has not yet announced commercial revenue.
- Company typePrivate
- Founded2025
- HeadquartersBeverly, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MantaBio does
MantaBio is a privately held, seed-stage life science tools startup founded in 2025 and headquartered in Beverly, Massachusetts. The company is developing a single microbial detection platform intended for biopharmaceutical manufacturers that need to identify microbial contamination during drug production. Its current product portfolio consists of one core platform in active development, with no other products, services, or commercial offerings disclosed in the available source data.
The platform is positioned to support pharmaceutical quality control workflows, with microbial contamination testing as its primary use case. MantaBio's go-to-market is vertically concentrated on biopharmaceutical manufacturers; no customers, pricing model, distribution channels, or revenue mechanics have been publicly disclosed. The company operates with a small team of 1–10 employees and was co-founded by Jack Regan (CEO) and Carter Boisfontaine (President), the two named members of its leadership.
In 2025, MantaBio closed a $2.5 million seed round to fund platform development — its only disclosed financing event. The company has not yet announced partnerships, regulatory milestones, certifications, intellectual property filings, or commercial deployments. Operating geographies, pricing strategy, and revenue model remain unspecified in publicly available sources, leaving the company's commercial mechanics as a key open question for diligence.
MantaBio firmographics
Firmographics- Name
- MantaBio
- Website
- https://mantabio.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MantaBio is a seed-stage life science tools startup developing an automated microbial detection platform for biopharmaceutical manufacturers to identify contamination during drug production. The Beverly, Massachusetts-based company is in active platform development and has not yet announced commercial revenue.
- Ownership category
- akta.pro rank
MantaBio industry classification
Industry- Product category
- Microbial Detection Instruments for Biopharmaceutical Manufacturing
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Testing Laboratories and Services (541380)
- SIC
- Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)
- akta.pro industry
- Environmental Monitoring & Cleanroom Testing (GMP)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical ServicesMicrobiology & Infectious Disease Testing Laboratories
Keywords
Where MantaBio is headquartered
LocationHeadquarters
- HQ city
- Beverly
- HQ country
- United States
- HQ region
- North America
Markets served
MantaBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
MantaBio product offering
Product offeringCore offering
MantaBio is developing a microbial contamination testing platform designed for biopharma applications. The platform is intended to enable detection and identification of microbial contaminants in pharmaceutical manufacturing environments and to support pharmaceutical quality control processes. The product is currently in active development at the seed stage.
Product overview
MantaBio is developing a single unified microbial detection platform for biopharma applications, focused specifically on microbial contamination testing. The platform is designed to support pharmaceutical quality control processes. As a seed-stage startup, the company currently offers one core product in active development.
Differentiator
Problem solved
Functional benefit
Products and services
- Microbial Detection Platform
Companies that use MantaBio
Customer profileSegments1 record
Ideal customer profiles1 record
MantaBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MantaBio partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
MantaBio competitors and assessment
Company assessmentDirect peers
- Rapid Micro Biosystems: Rapid Micro Biosystems sells the Growth Direct platform for automated, rapid microbial enumeration in pharmaceutical manufacturing QC, making it the closest direct peer to MantaBio's stated mission of automated microbial detection for biopharma.
Broad incumbents
- bioMérieux: bioMérieux is a global microbiology leader whose industrial microbiology portfolio (including the BioFire FilmArray line) serves biopharma contamination control; it sets the incumbent benchmark MantaBio must beat on installed base and validated methods.
- Charles River Laboratories: Charles River's Manufacturing Solutions segment offers endotoxin and microbial detection products and services (Endosafe, Accugenix) to biopharma QC labs, directly addressing the same contamination-testing workflows MantaBio targets.
- BD (Becton, Dickinson and Company): BD's Life Sciences segment supplies a broad range of microbiology media, instruments, and detection systems used in pharmaceutical and clinical QC, overlapping directly with MantaBio's biopharma microbial detection value proposition.
- Bio-Rad Laboratories: Bio-Rad supplies molecular and traditional microbiology instruments, reagents, and QC kits widely used in biopharma manufacturing environments, making it a key incumbent in the rapid and traditional microbial detection categories MantaBio is entering.
- Eurofins Scientific: Eurofins is a global testing services group with substantial pharmaceutical microbiology and sterility testing capacity; it is a comparable counterparty for biopharma QC spend and a potential customer, partner, or competitor to MantaBio.
- SGS: SGS provides life-sciences testing services including microbial and sterility testing for pharmaceutical manufacturers, operating as a large incumbent in the same biopharma contamination testing spend pool that MantaBio is targeting.
- MilliporeSigma (Merck KGaA Life Science): MilliporeSigma supplies bioprocessing consumables, instrumentation, and QC microbiology products to pharmaceutical manufacturers, overlapping with MantaBio's biopharma QC customer base and representing both a competitor and a potential channel partner.
- Lonza Group: Lonza is a leading CDMO and bioprocessing solutions provider with extensive in-house QC microbiology needs and adjacent product offerings, making it a relevant comparable for biopharma QC demand and potential partnership counterpart.
Emerging players
- QIAGEN: QIAGEN provides sample-prep and molecular detection solutions used in pharma QC and microbiology workflows; while broader in scope, its molecular-detection portfolio is technologically adjacent to a rapid microbial detection platform for biopharma.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
MantaBio social profiles
Digital presenceMantaBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
MantaBio leadership team
Management profileNumber of profiles
Profiles2 records
MantaBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MantaBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MantaBio
What does MantaBio do?
MantaBio is developing a microbial contamination testing platform designed for biopharma applications. The platform is intended to enable detection and identification of microbial contaminants in pharmaceutical manufacturing environments and to support pharmaceutical quality control processes. The product is currently in active development at the seed stage.
Is MantaBio a public or private company?
MantaBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was MantaBio founded?
MantaBio was founded in 2025. It employs 1 to 10 people.
Where is MantaBio based?
MantaBio is headquartered in Beverly, United States, in the North America region.
Who are MantaBio's main competitors?
Rapid Micro Biosystems is listed as a direct peer. Broad incumbents are bioMérieux, Charles River Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Eurofins Scientific, SGS, MilliporeSigma (Merck KGaA Life Science) and Lonza Group. QIAGEN is listed as an emerging player.
Does MantaBio have an API?
No public API is recorded for MantaBio.
What industry is MantaBio in?
MantaBio's product category is Microbial Detection Instruments for Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGADAL, Environmental Monitoring & Cleanroom Testing (GMP), with a secondary code of HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories. Its NAICS code is 334516 and its SIC code is 3826.